AFG3-like protein 2 Recombinant Protein | AFG3L2 recombinant protein
Recombinant Human AFG3-like protein 2
Gene Names
AFG3L2; SCA28; SPAX5
Purity
Greater or equal to 85% purity as determined by SDS-PAGE.
Synonyms
AFG3-like protein 2; N/A; Recombinant Human AFG3-like protein 2; Paraplegin-like protein; AFG3L2 recombinant protein
Host
E Coli
Purity/Purification
Greater or equal to 85% purity as determined by SDS-PAGE.
Form/Format
Liquid containing glycerol
Sequence Positions
550-759aa; Partial
Sequence
ERVIGGLEKKTQVLQPEEKKTVAYHEAGHAVAGWYLEHADPLLKVSIIPRGKGLGYAQYLPKEQYLYTKEQLLDRMCMTLGGRVSEEIFFGRITTGAQDDLRKVTQSAYAQIVQFGMNEKVGQISFDLPRQGDMVLEKPYSEATARLIDDEVRILINDAYKRTVALLTEKKADVEKVALLLLEKEVLDKNDMVELLGPRPFAEKSTYEEF
Sequence Length
797
Preparation and Storage
Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.
Related Product Information for AFG3L2 recombinant protein
ATP-dependent protease which is essential for axonal development.
Product Categories/Family for AFG3L2 recombinant protein
References
Identification and characterization of AFG3L2, a novel paraplegin-related gene.Banfi S., Bassi M.T., Andolfi G., Marchitiello A., Zanotta S., Ballabio A., Casari G., Franco B.Genomics 59:51-58(1999) Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia.Atorino L., Silvestri L., Koppen M., Cassina L., Ballabio A., Marconi R., Langer T., Casari G.J. Cell Biol. 163:777-787(2003) Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia.Koppen M., Metodiev M.D., Casari G., Rugarli E.I., Langer T.Mol. Cell. Biol. 27:758-767(2007) Initial characterization of the human central proteome.Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.BMC Syst. Biol. 5:17-17(2011) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., Zou H.J. Proteomics 96:253-262(2014) Northeast structural genomics consortium target HR6741A.Northeast structural genomics consortium (NESG) Submitted (MAR-2012) to the PDB data bankEarly onset and slow progression of SCA28, a rare dominant ataxia in a large four-generation family with a novel AFG3L2 mutation.Edener U., Wollner J., Hehr U., Kohl Z., Schilling S., Kreuz F., Bauer P., Bernard V., Gillessen-Kaesbach G., Zuhlke C.Eur. J. Hum. Genet. 18:965-968(2010) Missense mutations in the AFG3L2 proteolytic domain account for approximately 1.5% of European autosomal dominant cerebellar ataxias.Cagnoli C., Stevanin G., Brussino A., Barberis M., Mancini C., Margolis R.L., Holmes S.E., Nobili M., Forlani S., Padovan S., Pappi P., Zaros C., Leber I., Ribai P., Pugliese L., Assalto C., Brice A., Migone N., Durr A., Brusco A.Hum. Mutat. 31:1117-1124(2010) Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28.Di Bella D., Lazzaro F., Brusco A., Plumari M., Battaglia G., Pastore A., Finardi A., Cagnoli C., Tempia F., Frontali M., Veneziano L., Sacco T., Boda E., Brussino A., Bonn F., Castellotti B., Baratta S., Mariotti C., Gellera C., Fracasso V., Magri S., Langer T., Plevani P., Di Donato S., Muzi-Falconi M., Taroni F.Nat. Genet. 42:313-321(2010) Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases.Pierson T.M., Adams D., Bonn F., Martinelli P., Cherukuri P.F., Teer J.K., Hansen N.F., Cruz P., Mullikin J.C., Blakesley R.W., Golas G., Kwan J., Sandler A., Fuentes Fajardo K., Markello T., Tifft C., Blackstone C., Rugarli E.I., Langer T., Gahl W.A., Toro C.PLoS Genet. 7:E1002325-E1002325(2011)
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
Molecular Weight
50.8 kDa
NCBI Official Full Name
AFG3-like protein 2
NCBI Official Synonym Full Names
AFG3-like AAA ATPase 2
NCBI Official Symbol
AFG3L2
NCBI Official Synonym Symbols
SCA28; SPAX5
NCBI Protein Information
AFG3-like protein 2
UniProt Protein Name
AFG3-like protein 2
UniProt Gene Name
AFG3L2
UniProt Entry Name
AFG32_HUMAN
Similar Products
Product Notes
The AFG3L2 afg3l2 (Catalog #AAA116162) is a Recombinant Protein produced from E Coli and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 550-759aa; Partial. The amino acid sequence is listed below: ERVIGGLEKK TQVLQPEEKK TVAYHEAGHA VAGWYLEHAD PLLKVSIIPR GKGLGYAQYL PKEQYLYTKE QLLDRMCMTL GGRVSEEIFF GRITTGAQDD LRKVTQSAYA QIVQFGMNEK VGQISFDLPR QGDMVLEKPY SEATARLIDD EVRILINDAY KRTVALLTEK KADVEKVALL LLEKEVLDKN DMVELLGPRP FAEKSTYEEF. It is sometimes possible for the material contained within the vial of "AFG3-like protein 2, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
